PRINCIPIA BIOPHARMA REPORTS POSITIVE PRN1008 PHASE 2 TOP-LINE RESULTS AND INITIATES PHASE 3 PEMPHIGUS PROGRAM November 29, 2018 at 4:01 PM EST – Achieved Phase 2 primary endpoint – over 50% of patients attained Control of Disease Activity within four weeks of...
HARPOON THERAPEUTICS UNVEILS PROTRITAC PLATFORM: A NOVEL, PROTEASE-ACTIVATED T CELL ENGAGER PLATFORM DESIGNED TO ACCESS A BROAD LANDSCAPE OF SOLID TUMOR TARGETS Preclinical Proof-of-Concept Data Presented at the 2018 Society for Immunotherapy of Cancer (SITC) Annual...
HARPOON THERAPEUTICS ANNOUNCES CLOSING OF $70M SERIES C FINANCING Proceeds to Advance Pipeline of Cancer Immunotherapies South San Francisco, CA – November 11, 2018 – Harpoon Therapeutics, Inc. (“Harpoon”), a clinical-stage immunotherapy company developing a novel...
Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans Studies in Healthy Human Volunteers Reinforce Mechanism of Action Observed in Preclinical Studies EVANSTON, Ill.,...
Aptinyx Completes Enrollment in Phase 2 Study of NYX-2925 for Painful Diabetic Peripheral Neuropathy Top-line Data Expected Early in the First Quarter of 2019 EVANSTON, Ill., Nov. 01, 2018 (GLOBE NEWSWIRE) — Aptinyx Inc. (NASDAQ:APTX), a clinical-stage...
Recent Comments